Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Antibodies to endothelial cells in Behçet's disease: cell-binding heterogeneity and association with clinical activity

dc.contributor.authorCervera i Segura, Ricard, 1960-cat
dc.contributor.authorNavarro López, Margaritacat
dc.contributor.authorLópez-Soto, Alfonsocat
dc.contributor.authorCid Xutglà, M. Cintacat
dc.contributor.authorFont Franco, Josep, 1953-2006cat
dc.contributor.authorEsparza Sánchez, Jordicat
dc.contributor.authorReverter Calatayud, Juan Carloscat
dc.contributor.authorMonteagudo Terres, Juancat
dc.contributor.authorIngelmo Morín, Miguelcat
dc.contributor.authorUrbano Márquez, A. (Álvaro)cat
dc.date.accessioned2012-03-05T12:52:14Z
dc.date.available2012-03-05T12:52:14Z
dc.date.issued1994
dc.description.abstractOBJECTIVES--To investigate the prevalence and characteristics of antibodies to endothelial cells (aEC) from large vessel and from microvasculature in a group of patients with Behçet's disease (BD) to determine the relationship of these antibodies with clinical and laboratory features of the disease. METHODS--Thirty patients with BD were prospectively and consecutively studied. The aEC were determined by enzyme-linked immunosorbent assay (ELISA) using endothelial cells derived from human umbilical vein (large vessel) as well as from retroperitoneal adipose tissue (microvasculature). RESULTS--Fifteen patients (50%) had aEC, either directed to large vessel [8(26%) patients] or microvascular [13(43%) patients] endothelial cells. The percentage of active patients was significantly higher in the aEC-positive group [12(80%) patients] compared with the aEC-negative group [5(33%) patients] (p < 0.05). CONCLUSIONS--Patients with BD have a high prevalence of aEC when microvascular endothelial cells are used in the assay. These antibodies seem to be a marker of disease activity in this condition, previously considered as negative for autoantibodies.
dc.format.extent3 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec101197
dc.identifier.issn0003-4967
dc.identifier.pmid8203957
dc.identifier.pmid25774787
dc.identifier.urihttps://hdl.handle.net/2445/22459
dc.language.isoengeng
dc.publisherBMJ Group
dc.relation.isformatofReproducció digital del document publicat a: http://dx.doi.org/10.1136/ard.53.4.265
dc.relation.ispartofAnnals of the Rheumatic Diseases, 1994, vol. 53, núm. 4, p. 265-267
dc.relation.urihttp://dx.doi.org/10.1136/ard.53.4.265
dc.rights(c) BMJ Publishing Group Ltd, 1994
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalaltia de Behçetcat
dc.subject.classificationEndotelicat
dc.subject.classificationAutoanticossoscat
dc.subject.classificationImmunoglobulinescat
dc.subject.otherBehçet's diseaseeng
dc.subject.otherEndotheliumeng
dc.subject.otherAutoantibodieseng
dc.subject.otherImmunoglobulinseng
dc.titleAntibodies to endothelial cells in Behçet's disease: cell-binding heterogeneity and association with clinical activityeng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
101197.pdf
Mida:
584.16 KB
Format:
Adobe Portable Document Format